Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00103740
Status:
COMPLETED
Last Update Posted:
2012-06-04
First Post:
2005-02-14
Brief Title:
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Pagets Disease of Bone Including an Extended Observation Period
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Randomized Double-Blind Safety and Efficacy Trial With Intravenous Zoledronic Acid for the Treatment of Pagets Disease of Bone Using Risedronate as a Comparator Including an Extended Observation Period
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this core study was to show non-inferiority of zoledronic acid to risedronate with respect to the proportion of patients who achieved therapeutic response The extended observation period included participants of the core study who responded to treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ZOL446K2305 | OTHER | Novartis Pharmaceuticals | None |